An interventional study of Conventional treatment and TECAR (Transfer of Energy Capacitive and Resistive) Therapy in Supraspinatus Tendinitis, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Tendinopathy by Cairo University — 4 open to participants now, 4 under way, none of them phase 3. Tendinopathy · Cairo University.
Among the 10 studies in Tendinopathy by Cairo University, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 10 with no phase, and was the 7th registered.
399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →4 of the 10 studies in Tendinopathy by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–50
Cairo University · Sites in Egypt
Ages 18–65
Cairo University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 30 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 46 is close to the median of 48 across 333 interventional studies indexed under Tendinopathy.
Median enrollment 50 across the 10 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
2 of the studies in Tendinopathy by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07794033Cairo UniversityEffect of TECAR on Supraspinatus Tendon Thickness in Supraspinatus Tendinitis | 2027-04-10 |
| NCT07667998Cairo UniversityHigh-intensity Laser Therapy Versus Extracorporeal Shock Wave on Tendon Thickness and Occupation Ratio In Patients With Chronic Supraspinatus Tendinopathy | 2027-04-25 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Tendinopathy by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis.
Tendinopathy occurs when pain arises in a tendon near its origin or insertion due to repetitive activities and reduced functional levels. It happens when the tendon does not properly heal. Thirty percent of tendinopathies related to musculoskeletal conditions are associated with shoulder pain, and supraspinatus tendinitis is the third most prevalent problem.
The supraspinatus tendon, part of the rotator cuff of the shoulder joint, is particularly affected. Aging is also a common factor leading to supraspinatus tendon injuries. The primary function of the supraspinatus muscle is shoulder abduction, particularly during movements that elevate the arm overhead. During these motions, the supraspinatus tendon repeatedly passes beneath the acromion process of the scapula, which can result in impingement and subsequent inflammation. An unexpected force or trauma may cause a partial or complete tendon rupture if this condition progresses.
Transfer of Energy Capacitive and Resistive (TECAR) offers a unique variety of treatments for chronic and acute pathologies, with contraindications such as pregnancy, pacemakers, and sensitivity to high temperatures. It should be noted that this new technology is a valuable tool in treating various pathologies, particularly when compared with other therapies in terms of the presence and/or absence of specific positive effects. TECAR also has distinct characteristics that are effective even when other treatments fail. This therapy balances the therapist's manual skills and the specialized energy that this technology offers, resulting in increasingly satisfactory outcomes for therapists and patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental group will receive conventional physiotherapy sessions as the active comparator group, in addition to TECAR therapy at the end of each session. Sessions will be received for three weeks (nine sessions, three times per week).
Other: Conventional treatment · Device: TECAR (Transfer of Energy Capacitive and Resistive) Therapy
The active comparator group will receive conventional physiotherapy sessions for three weeks (nine sessions, three times per week).
Other: Conventional treatment
All patients in both groups will receive conventional treatment, 3 sessions per week for 3 weeks. The conventional methods for treating supraspinatus tendinitis include shoulder swings, painless range of motion (ROM) exercises, shoulder joint active-assisted exercises, resistance exercises to improve muscle strength, and pain-reducing physiotherapy modalities like ultrasound.
Patients in the experimental group only will receive TECAR therapy, 3 sessions per week for 3 weeks. The treatment will start with an automatic capacitive energy transfer for 10 minutes. Next, the capacitive plaque will be replaced by the resistive electrode, and the neutral electrode will be fixed
Assessment of Pain Intensity of Shoulder Joint by Numerical Rating Scale (NRS)
The Numerical Rating Scale (NRS) will evaluate shoulder pain when using the NRS. Patients will be asked to rate their pain on a scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain possible.
Time frame: 3 weeks
Assessment of Shoulder abduction range of motion
A digital goniometer will be used to assess shoulder joint abduction range of motion in patients with chronic supraspinatus tendinitis before and after the treatment sessions. Measurements will be taken with the patient in the supine position. The fulcrum of the goniometer will be centered at the anterior aspect of the acromion process, the stationary arm will be aligned parallel to the midline of the torso, and the moving arm will be aligned with the midline of the humerus, pointing toward the medial epicondyle of the elbow.
Time frame: 3 weeks
Assessment of Shoulder External Rotation range of motion
Shoulder joint external rotation range of motion will also be assessed using a digital goniometer before and after the treatment sessions in patients with chronic supraspinatus tendinitis. The patient will be positioned supine during measurement. The fulcrum of the goniometer will be centered over the olecranon process of the elbow, the stationary arm will be aligned perpendicular to the floor, and the moving arm will be aligned with the ulna, pointing toward the ulnar styloid process.
Time frame: 3 weeks
Assessment of Handgrip strength by handheld dynamometer
A JAMAR hand dynamometer (Sammons Preston Inc, Bolingbrook, IL, USA) will be used to measure grip strength in kilograms. The Jamar is small and portable but relatively heavy at 1.5 lb. The dial reads force in both kilograms and pounds, with markings at intervals of 2 kg or 5 lb, allowing assessment to the nearest 1 kg or 2.5 lb. The reading error is reported to be greater at lower loadings. This method has high test-retest reliability. Also, it has both inter and intra-rater reliability.
Time frame: 3 weeks
Assessment of Functional disability by QuickDASH Scale (Arabic Version)
The QuickDASH includes 30 items, with six items about symptoms (3 about pain, 1 for tingling/numbness, 1 for weakness, 1 for stiffness) and 24 about function (21 about physical function, 3 about social/role function). For each question, the subject rated the performance in the last week on a 5-point scale (1 = no difficulty to perform or no impact; 5 = unable to do or high impact). The raw score is the sum of all answers (maximum score: 150; minimum score: 30). The raw score is transformed into a zero to 100 scale (= total DASH). Zero is no disability and 100 maximum disability.
Time frame: 3 weeks
Start is estimated for Dec 2025; primary completion for Feb 2026, 1 month later.
Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's planned 1 month is below that.
Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.